Literature DB >> 8101840

Identification of the specific oligosaccharide sites recognized by type 1 fimbriae from Escherichia coli on nonspecific cross-reacting antigen, a CD66 cluster granulocyte glycoprotein.

S L Sauter1, S M Rutherfurd, C Wagener, J E Shively, S A Hefta.   

Abstract

Nonspecific cross-reacting antigen (NCA), a CD66 cluster antigen, is a well characterized glycoprotein on granulocytes, macrophages, and lung epithelium. Structural studies at the protein and genomic levels have revealed that NCA is a member of the immunoglobulin (Ig) supergene family and contains a domain structure similar to Ig with an amino-terminal variable-like domain followed by disulfide loop-containing constant-like domains. Previous work by this laboratory and others has demonstrated that NCA is a receptor for binding of bacteria expressing type 1 fimbriae (pili). This binding is mediated by interaction between lectins on the bacteria fimbriae and carbohydrate chains on NCA. In the present work we further characterize the specificity for bacterial binding by NCA using endoglycosidases and site-directed mutagenesis. Results of these studies demonstrate that Escherichia coli expressing type 1 fimbriae binds to high mannose oligosaccharide structures on NCA and that the functionally relevant sites are located in the variable-like domain of NCA.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8101840

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

Review 1.  Potential role of chitinases and chitin-binding proteins in host-microbial interactions during the development of intestinal inflammation.

Authors:  H T Tran; N Barnich; E Mizoguchi
Journal:  Histol Histopathol       Date:  2011-11       Impact factor: 2.303

Review 2.  Covert operations of uropathogenic Escherichia coli within the urinary tract.

Authors:  Jean M Bower; Danelle S Eto; Matthew A Mulvey
Journal:  Traffic       Date:  2005-01       Impact factor: 6.215

3.  Role of nonspecific cross-reacting antigen, a CD66 cluster antigen, in activation of human granulocytes.

Authors:  M L Klein; S A McGhee; J Baranian; L Stevens; S A Hefta
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

4.  Secretion of type-1-fimbriae binding proteins from human neutrophil granulocytes.

Authors:  A Karlsson; C Dahlgren
Journal:  Inflammation       Date:  1996-08       Impact factor: 4.092

5.  Enterococcus faecalis bearing aggregation substance is resistant to killing by human neutrophils despite phagocytosis and neutrophil activation.

Authors:  R M Rakita; N N Vanek; K Jacques-Palaz; M Mee; M M Mariscalco; G M Dunny; M Snuggs; W B Van Winkle; S I Simon
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

6.  CGM1a antigen of neutrophils, a receptor of gonococcal opacity proteins.

Authors:  T Chen; E C Gotschlich
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

7.  Expression of adhesion molecules on human granulocytes after stimulation with Helicobacter pylori membrane proteins: comparison with membrane proteins from other bacteria.

Authors:  G Enders; W Brooks; N von Jan; N Lehn; E Bayerdörffer; R Hatz
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

8.  CEACAM1 recognition by bacterial pathogens is species-specific.

Authors:  Maike Voges; Verena Bachmann; Robert Kammerer; Uri Gophna; Christof R Hauck
Journal:  BMC Microbiol       Date:  2010-04-20       Impact factor: 3.605

9.  Uropathogenic Escherichia coli triggers oxygen-dependent apoptosis in human neutrophils through the cooperative effect of type 1 fimbriae and lipopolysaccharide.

Authors:  Robert Blomgran; Limin Zheng; Olle Stendahl
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

10.  CD66 receptor specificity exhibited by neisserial Opa variants is controlled by protein determinants in CD66 N-domains.

Authors:  M P Bos; M Kuroki; A Krop-Watorek; D Hogan; R J Belland
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.